The new FreeStyle libre flash glucose monitoring system improves the glycaemic control in a cohort of people with type 1 diabetes followed in real‐life conditions over a period of one year
Summary Aims Using the novel FreeStyle Libre (FSL), glucose monitoring (FGM) system becomes increasingly popular among people with type 1 diabetes (T1D) and is associated with less and shorter hypoglycaemic events without deterioration of HbA1c. There are not yet data reporting the impact of FGM in...
Gespeichert in:
| Veröffentlicht in: | Endocrinology, diabetes & metabolism diabetes & metabolism, 2018-07, Vol.1 (3), p.e00023-n/a |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 3 |
| container_start_page | e00023 |
| container_title | Endocrinology, diabetes & metabolism |
| container_volume | 1 |
| creator | Paris, Isabelle Henry, Corinne Pirard, Françoise Gérard, Anne‐Catherine Colin, Ides M. |
| description | Summary
Aims
Using the novel FreeStyle Libre (FSL), glucose monitoring (FGM) system becomes increasingly popular among people with type 1 diabetes (T1D) and is associated with less and shorter hypoglycaemic events without deterioration of HbA1c. There are not yet data reporting the impact of FGM in people with T1D in real‐life conditions. We sought of evaluating the tolerance, the acceptance and the efficacy of the FGM system in routine medical practice.
Methods
This 12‐month observational study included 120 individuals with T1D evaluated every 3 months. After having been instructed about FGM utilization, participants were trained to optimize the glycaemic control.
Results
Participants stopped immediately of measuring capillary blood glucose (2.88 ± 0.12 per day) (mean ± SEM) after having received the first FSL device and the number of scans per day increased up to 8.87 ± 0.58 per day. HbA1c levels decreased from 8.51% ± 0.14% at baseline to 7.77% ± 0.09% after 3 months to slightly increase to 7.92% ± 0.09% at 12 months, in correlation with the number of scans per day. The number (but not the duration) of hypoglycaemic events slightly increased from 16.9 ± 1.44 per month at baseline to 24.0 ± 2.91 per month at 12 months, after reaching a peak of 26.4 ± 2.31 per month at 6 months. They were correlated with improved HbA1c.
Conclusion
Our study shows that using the FGM system improves HbA1c levels in people with T1D along with a moderate increase in the number of mild hypoglycaemic events. The new FGM system facilitates the therapeutic empowerment of people with T1D, but in a context of structured education.
FGM system improves HbA1c levels in people with T1D along with a moderate increase in the number of mild hypoglycaemic events. This new technology provides real‐time reliable glucose information and glucose trends that are proactively used by people with type 1 diabetes for fine‐tuning therapeutic decision and adaptation of insulin dosages. |
| doi_str_mv | 10.1002/edm2.23 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6354746</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2187030219</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3633-92dfb4b21cdf783c920922020af93a37c1fde5e11d6b7fd9aca0614b3912ff133</originalsourceid><addsrcrecordid>eNp1ks1qFTEUxwdRbKnFN5CACwW5NR93PrIRpLZVqLiwrkMmObk3JZOMSaaX2fkIPpEP45M0w62lCq6SkF9-53_CqarnBJ8QjOlb0AM9oexRdUgZ71acsu7xg_1BdZzSNcaYcM4bTJ9WBwx3pK7r9rD6dbUF5GGHziPA1zw7QM72EZBxMm3Rxk0qJEBD8DaHaP0GpTllGJAdxhhuIKFcBBs3KwmDVUgFn2NwyHoky2EbYkbBoBHCWNQ7m7cozyMggrSVPeQiMMG5sAO9vIkg3e8fP501sKi0zTb4hEqhWHwjRBv04gse0AwyPqueGOkSHN-tR9W387Or04-ryy8Xn07fX64Uaxgr36BNv-4pUdq0HVOcYk4pplgaziRrFTEaaiBEN31rNJdK4oase8YJNYYwdlS923vHqR9AKyhdSifGaAcZZxGkFX_feLsVm3AjGlav23VTBK_vBDF8nyBlMdikwDnpIUxJUNK1mGFKeEFf_oNehyn60p6gtGm6ljT1Iny1p1QMKUUw92EIFstYiGUsBF2yv3iY_Z77MwQFeLMHdtbB_D-POPvwmRbdLW8-xbU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2266871656</pqid></control><display><type>article</type><title>The new FreeStyle libre flash glucose monitoring system improves the glycaemic control in a cohort of people with type 1 diabetes followed in real‐life conditions over a period of one year</title><source>PubMed (Medline)</source><source>Wiley Online Library</source><source>Wiley Open Access</source><source>Directory of Open Access Journals</source><source>EZB Electronic Journals Library</source><creator>Paris, Isabelle ; Henry, Corinne ; Pirard, Françoise ; Gérard, Anne‐Catherine ; Colin, Ides M.</creator><creatorcontrib>Paris, Isabelle ; Henry, Corinne ; Pirard, Françoise ; Gérard, Anne‐Catherine ; Colin, Ides M.</creatorcontrib><description>Summary
Aims
Using the novel FreeStyle Libre (FSL), glucose monitoring (FGM) system becomes increasingly popular among people with type 1 diabetes (T1D) and is associated with less and shorter hypoglycaemic events without deterioration of HbA1c. There are not yet data reporting the impact of FGM in people with T1D in real‐life conditions. We sought of evaluating the tolerance, the acceptance and the efficacy of the FGM system in routine medical practice.
Methods
This 12‐month observational study included 120 individuals with T1D evaluated every 3 months. After having been instructed about FGM utilization, participants were trained to optimize the glycaemic control.
Results
Participants stopped immediately of measuring capillary blood glucose (2.88 ± 0.12 per day) (mean ± SEM) after having received the first FSL device and the number of scans per day increased up to 8.87 ± 0.58 per day. HbA1c levels decreased from 8.51% ± 0.14% at baseline to 7.77% ± 0.09% after 3 months to slightly increase to 7.92% ± 0.09% at 12 months, in correlation with the number of scans per day. The number (but not the duration) of hypoglycaemic events slightly increased from 16.9 ± 1.44 per month at baseline to 24.0 ± 2.91 per month at 12 months, after reaching a peak of 26.4 ± 2.31 per month at 6 months. They were correlated with improved HbA1c.
Conclusion
Our study shows that using the FGM system improves HbA1c levels in people with T1D along with a moderate increase in the number of mild hypoglycaemic events. The new FGM system facilitates the therapeutic empowerment of people with T1D, but in a context of structured education.
FGM system improves HbA1c levels in people with T1D along with a moderate increase in the number of mild hypoglycaemic events. This new technology provides real‐time reliable glucose information and glucose trends that are proactively used by people with type 1 diabetes for fine‐tuning therapeutic decision and adaptation of insulin dosages.</description><identifier>ISSN: 2398-9238</identifier><identifier>EISSN: 2398-9238</identifier><identifier>DOI: 10.1002/edm2.23</identifier><identifier>PMID: 30815557</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Clinical trials ; Diabetes ; diabetes management ; FreeStyle libre ; Glucose ; glucose monitoring ; Hypoglycemia ; Insulin ; Monitoring systems ; Original ; real‐life conditions ; Sensors</subject><ispartof>Endocrinology, diabetes & metabolism, 2018-07, Vol.1 (3), p.e00023-n/a</ispartof><rights>2018 The Authors. published by John Wiley & Sons Ltd.</rights><rights>2018. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3633-92dfb4b21cdf783c920922020af93a37c1fde5e11d6b7fd9aca0614b3912ff133</citedby><cites>FETCH-LOGICAL-c3633-92dfb4b21cdf783c920922020af93a37c1fde5e11d6b7fd9aca0614b3912ff133</cites><orcidid>0000-0003-2332-5628</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354746/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354746/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1411,11541,27901,27902,45550,45551,46027,46451,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30815557$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Paris, Isabelle</creatorcontrib><creatorcontrib>Henry, Corinne</creatorcontrib><creatorcontrib>Pirard, Françoise</creatorcontrib><creatorcontrib>Gérard, Anne‐Catherine</creatorcontrib><creatorcontrib>Colin, Ides M.</creatorcontrib><title>The new FreeStyle libre flash glucose monitoring system improves the glycaemic control in a cohort of people with type 1 diabetes followed in real‐life conditions over a period of one year</title><title>Endocrinology, diabetes & metabolism</title><addtitle>Endocrinol Diabetes Metab</addtitle><description>Summary
Aims
Using the novel FreeStyle Libre (FSL), glucose monitoring (FGM) system becomes increasingly popular among people with type 1 diabetes (T1D) and is associated with less and shorter hypoglycaemic events without deterioration of HbA1c. There are not yet data reporting the impact of FGM in people with T1D in real‐life conditions. We sought of evaluating the tolerance, the acceptance and the efficacy of the FGM system in routine medical practice.
Methods
This 12‐month observational study included 120 individuals with T1D evaluated every 3 months. After having been instructed about FGM utilization, participants were trained to optimize the glycaemic control.
Results
Participants stopped immediately of measuring capillary blood glucose (2.88 ± 0.12 per day) (mean ± SEM) after having received the first FSL device and the number of scans per day increased up to 8.87 ± 0.58 per day. HbA1c levels decreased from 8.51% ± 0.14% at baseline to 7.77% ± 0.09% after 3 months to slightly increase to 7.92% ± 0.09% at 12 months, in correlation with the number of scans per day. The number (but not the duration) of hypoglycaemic events slightly increased from 16.9 ± 1.44 per month at baseline to 24.0 ± 2.91 per month at 12 months, after reaching a peak of 26.4 ± 2.31 per month at 6 months. They were correlated with improved HbA1c.
Conclusion
Our study shows that using the FGM system improves HbA1c levels in people with T1D along with a moderate increase in the number of mild hypoglycaemic events. The new FGM system facilitates the therapeutic empowerment of people with T1D, but in a context of structured education.
FGM system improves HbA1c levels in people with T1D along with a moderate increase in the number of mild hypoglycaemic events. This new technology provides real‐time reliable glucose information and glucose trends that are proactively used by people with type 1 diabetes for fine‐tuning therapeutic decision and adaptation of insulin dosages.</description><subject>Clinical trials</subject><subject>Diabetes</subject><subject>diabetes management</subject><subject>FreeStyle libre</subject><subject>Glucose</subject><subject>glucose monitoring</subject><subject>Hypoglycemia</subject><subject>Insulin</subject><subject>Monitoring systems</subject><subject>Original</subject><subject>real‐life conditions</subject><subject>Sensors</subject><issn>2398-9238</issn><issn>2398-9238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>BENPR</sourceid><recordid>eNp1ks1qFTEUxwdRbKnFN5CACwW5NR93PrIRpLZVqLiwrkMmObk3JZOMSaaX2fkIPpEP45M0w62lCq6SkF9-53_CqarnBJ8QjOlb0AM9oexRdUgZ71acsu7xg_1BdZzSNcaYcM4bTJ9WBwx3pK7r9rD6dbUF5GGHziPA1zw7QM72EZBxMm3Rxk0qJEBD8DaHaP0GpTllGJAdxhhuIKFcBBs3KwmDVUgFn2NwyHoky2EbYkbBoBHCWNQ7m7cozyMggrSVPeQiMMG5sAO9vIkg3e8fP501sKi0zTb4hEqhWHwjRBv04gse0AwyPqueGOkSHN-tR9W387Or04-ryy8Xn07fX64Uaxgr36BNv-4pUdq0HVOcYk4pplgaziRrFTEaaiBEN31rNJdK4oase8YJNYYwdlS923vHqR9AKyhdSifGaAcZZxGkFX_feLsVm3AjGlav23VTBK_vBDF8nyBlMdikwDnpIUxJUNK1mGFKeEFf_oNehyn60p6gtGm6ljT1Iny1p1QMKUUw92EIFstYiGUsBF2yv3iY_Z77MwQFeLMHdtbB_D-POPvwmRbdLW8-xbU</recordid><startdate>201807</startdate><enddate>201807</enddate><creator>Paris, Isabelle</creator><creator>Henry, Corinne</creator><creator>Pirard, Françoise</creator><creator>Gérard, Anne‐Catherine</creator><creator>Colin, Ides M.</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2332-5628</orcidid></search><sort><creationdate>201807</creationdate><title>The new FreeStyle libre flash glucose monitoring system improves the glycaemic control in a cohort of people with type 1 diabetes followed in real‐life conditions over a period of one year</title><author>Paris, Isabelle ; Henry, Corinne ; Pirard, Françoise ; Gérard, Anne‐Catherine ; Colin, Ides M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3633-92dfb4b21cdf783c920922020af93a37c1fde5e11d6b7fd9aca0614b3912ff133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Clinical trials</topic><topic>Diabetes</topic><topic>diabetes management</topic><topic>FreeStyle libre</topic><topic>Glucose</topic><topic>glucose monitoring</topic><topic>Hypoglycemia</topic><topic>Insulin</topic><topic>Monitoring systems</topic><topic>Original</topic><topic>real‐life conditions</topic><topic>Sensors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Paris, Isabelle</creatorcontrib><creatorcontrib>Henry, Corinne</creatorcontrib><creatorcontrib>Pirard, Françoise</creatorcontrib><creatorcontrib>Gérard, Anne‐Catherine</creatorcontrib><creatorcontrib>Colin, Ides M.</creatorcontrib><collection>Wiley Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Endocrinology, diabetes & metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Paris, Isabelle</au><au>Henry, Corinne</au><au>Pirard, Françoise</au><au>Gérard, Anne‐Catherine</au><au>Colin, Ides M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The new FreeStyle libre flash glucose monitoring system improves the glycaemic control in a cohort of people with type 1 diabetes followed in real‐life conditions over a period of one year</atitle><jtitle>Endocrinology, diabetes & metabolism</jtitle><addtitle>Endocrinol Diabetes Metab</addtitle><date>2018-07</date><risdate>2018</risdate><volume>1</volume><issue>3</issue><spage>e00023</spage><epage>n/a</epage><pages>e00023-n/a</pages><issn>2398-9238</issn><eissn>2398-9238</eissn><abstract>Summary
Aims
Using the novel FreeStyle Libre (FSL), glucose monitoring (FGM) system becomes increasingly popular among people with type 1 diabetes (T1D) and is associated with less and shorter hypoglycaemic events without deterioration of HbA1c. There are not yet data reporting the impact of FGM in people with T1D in real‐life conditions. We sought of evaluating the tolerance, the acceptance and the efficacy of the FGM system in routine medical practice.
Methods
This 12‐month observational study included 120 individuals with T1D evaluated every 3 months. After having been instructed about FGM utilization, participants were trained to optimize the glycaemic control.
Results
Participants stopped immediately of measuring capillary blood glucose (2.88 ± 0.12 per day) (mean ± SEM) after having received the first FSL device and the number of scans per day increased up to 8.87 ± 0.58 per day. HbA1c levels decreased from 8.51% ± 0.14% at baseline to 7.77% ± 0.09% after 3 months to slightly increase to 7.92% ± 0.09% at 12 months, in correlation with the number of scans per day. The number (but not the duration) of hypoglycaemic events slightly increased from 16.9 ± 1.44 per month at baseline to 24.0 ± 2.91 per month at 12 months, after reaching a peak of 26.4 ± 2.31 per month at 6 months. They were correlated with improved HbA1c.
Conclusion
Our study shows that using the FGM system improves HbA1c levels in people with T1D along with a moderate increase in the number of mild hypoglycaemic events. The new FGM system facilitates the therapeutic empowerment of people with T1D, but in a context of structured education.
FGM system improves HbA1c levels in people with T1D along with a moderate increase in the number of mild hypoglycaemic events. This new technology provides real‐time reliable glucose information and glucose trends that are proactively used by people with type 1 diabetes for fine‐tuning therapeutic decision and adaptation of insulin dosages.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>30815557</pmid><doi>10.1002/edm2.23</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-2332-5628</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2398-9238 |
| ispartof | Endocrinology, diabetes & metabolism, 2018-07, Vol.1 (3), p.e00023-n/a |
| issn | 2398-9238 2398-9238 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6354746 |
| source | PubMed (Medline); Wiley Online Library; Wiley Open Access; Directory of Open Access Journals; EZB Electronic Journals Library |
| subjects | Clinical trials Diabetes diabetes management FreeStyle libre Glucose glucose monitoring Hypoglycemia Insulin Monitoring systems Original real‐life conditions Sensors |
| title | The new FreeStyle libre flash glucose monitoring system improves the glycaemic control in a cohort of people with type 1 diabetes followed in real‐life conditions over a period of one year |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T17%3A24%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20new%20FreeStyle%20libre%20flash%20glucose%20monitoring%20system%20improves%20the%20glycaemic%20control%20in%20a%20cohort%20of%20people%20with%20type%201%20diabetes%20followed%20in%20real%E2%80%90life%20conditions%20over%20a%20period%20of%20one%20year&rft.jtitle=Endocrinology,%20diabetes%20&%20metabolism&rft.au=Paris,%20Isabelle&rft.date=2018-07&rft.volume=1&rft.issue=3&rft.spage=e00023&rft.epage=n/a&rft.pages=e00023-n/a&rft.issn=2398-9238&rft.eissn=2398-9238&rft_id=info:doi/10.1002/edm2.23&rft_dat=%3Cproquest_pubme%3E2187030219%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2266871656&rft_id=info:pmid/30815557&rfr_iscdi=true |